





The tumor suppressor p53 plays a significant role in a variety of cellular functions including DNA 
repair, cell cycle modulation, and programmed cell death, also called apoptosis.1 Mutations or 
functional inactivation of p53 is a hallmark in many cancer types, such as breast and colorectal cancer, 
affecting greater than 22 million people.1 Approximately half of these patients display mutant p53 that 
has lost its tumor suppressor function, while the other half exhibit decreased p53 levels due to 
overexpression of the E3 ubiquitin ligases murine double minute 2 (MDM2) and MDMX.  MDM2 
decreases p53 levels by acting as a transcriptional inhibitor and as an E3 ligase facilitating degradation 
of p53 via the proteasome.1 In fact, there is overwhelming molecular and genetic evidence that the 
major role of MDM2, and its related complexes, is the targeting of p53 for proteasomal degradation.4 
Conversely, overexpression of p53 has been linked to the up-regulation of genes involved in cellular 
growth and apoptosis. Due to this, p53 has become an attractive therapeutic target by being the most 
frequently mutated gene in human cancer that not only plays a vital role in cellular function, but also 
has been proven to rescue apoptotic pathways in cancer cells.5 6 
 
In eukaryotic cells, the pathway for protein degradation via ubiquitination is commonly referred to as 
the ubiquitin proteasome system (UPS).7 Ubiquitination requires an increasingly complex enzymatic 
cascade involving E1 
ubiquitin activating 
enzymes, E2 ubiquitin 
conjugating enzymes, and 
E3 ubiquitin ligases (Figure 
1). First, free ubiquitin 
becomes conjugated to an 
E1 enzyme via a high-
energy thioester bond 
(Figure 1B).  Next, the 
ubiquitin is transferred from 
E1 to the active site on an 
E2 ubiquitin conjugating 
enzyme, forming an E2~Ub 
complex (Figure 1C).  
Finally, an E3 ubiquitin 
ligase facilitates the transfer 
of ubiquitin from E2 to a 
lysine residue on the target 
protein (labeled substrate, 
Figure 1D). The E3 ligase 
recognizes and 
ubiquitinates the protein 
through the recognition of a 
short amino acid sequence 
termed a degradation 
sequence, or degron.8 
Finally, multiple ubiquitins 
Figure 1. Overview of the ubiquitin proteasome system (UPS). Protein 
ubiquitination requires a series of enzymatic reactions starting with free 
ubiquitin (A) binding an E1 enzyme (B). Ub is then transferred from E1 to an 
E2 enzyme (C) and then finally to an E3 ligase (D) resulting in a polyUb chain. 
Ub is removed from the protein by a DUB (E). Ubiquitinated proteins then 
move on to impact signaling pathways (F) or are degraded by the 26S 





are sequentially added to the protein to form a polyubiquitin chain (a process termed 
polyubiquitination), effectively targeting the protein for degradation by the 26S proteasome complex 
(Figure 1G). 
 
The development of therapeutic methods relating the numerous 
biomolecular interactions of p53 in oncogenic signaling 
pathways has been steadily progressing in recent years. For 
instance, efforts to restore the deregulated p53 pathway, such as 
small-molecule inhibitors of the p53-MDM2 interaction, p53 
chaperone drugs, p53 gene therapy, and MDM2 inhibitors, are 
currently in clinical trials.6 Although a myriad of therapeutic 
opportunities to restore p53 function have been attempted, the 
most common approach has been to inhibit the function of 
proteins that reduce p53 amount and activity in cells.  A majority 
of efforts and clinical trials are focused around small drugs that 
block the protein-protein interaction between p53 and HDM2, 
the human protein analog of MDM2.  Drug discovery research 
has found peptides with higher affinities for the MDM2/HDM2 
binding domain than p53, reinforcing the notion that the binding 
pocket of MDM2 can be inhibited effectively, as exemplified in 
Figure 2. The vast library of MDM2 inhibitors includes nutlin, 
benzodiazepinedione, chromenotriazolopyrimidine, terphenyls, 
chalcones, MI-219, RG7112, and many others that exhibit good 
pharmokinetic and pharmacodynamics properties.6 Additionally, 
a class of novel compounds termed stapled peptides has been 
developed to inhibit the p53-MDM2 interaction with more 
comprehensive and potent effects. The stapled peptide sMTide-
02 was proven to display greater specificity and potency in its 
biological mechanism of MDM2 inhibition than previously 
identified inhibitors like nutlin and SAH-8.9 Molecules such as 
these stapled peptides are still under biochemical investigation in 
the hopes of reaching clinical trials and becoming powerful 
therapeutic tools. In addition to expanding the p53 related 
therapeutics library, research has progressed toward therapeutic 
characterization and evaluation, demonstrating that p53-targeted 
therapeutics must be sensitively controlled in order to achieve 
maximum tumor cell eliminations without bringing about toxicity to normal proliferating tissues. For 
instance, using murine models, researchers have indicated that therapies restoring wild-type p53 
function can lead to apoptosis in normal, healthy tissues. Accordingly, one must control the intensity 
and duration of p53 response via precise activation or rescue p53 function.6 
 
This expanding library of MDM2 inhibitors, combined with ongoing efforts to further explore the 
inhibitory mechanism of the MDM2-p53 binding interaction demonstrates how the ubiquitin-mediated 
degradation of p53 via MDM2 activity has become the focal point of p53 related cancer drug 
discovery. The establishment of this biomolecular target niche, combined with the potential issues and 
restraints regarding therapeutic mechanism sensitivity, highlights the dire need for precise analytical 
Figure 2. p53-HDM2 interaction as 
a drug target.  (A) The interaction 
between the E3 ligase HDM2 (green) 
and the amino acid residues of a p53-
binding domain (grey, blue, red). The 
diagram illustrates how p53 residues 
fit into a 3D pocket on the surface of 
HDM2 (B) A structural comparison 
of HDM2-bound nutlin (green), 
which is one of many small 
molecules under therapeutic 
exploration with p53 (grey). Nutlin 
inhibits the p53-HDM2 interaction 
by emulating the natural interaction 
of the p53 binding domain and the 
3D pocket of HDM2. Reproduced 




tools to evaluate the p53-MDM2 interaction in the UPS.10 In order to address this need, this project 
aims to develop a new biomolecular probe able to measure MDM2 activity. Specifically, the biosensor 
will be based on a degradation sequence of p53, allowing for recognition and binding by the E3 ligase 
MDM2. 
 
Previous work in our lab has focused on the identification and characterization of novel recognition 
substrates based on naturally occurring degrons from various proteins involved in the UPS related to 
oncogenic signaling pathways. These degron-based substrates incorporated naturally occurring degrons 
to facilitate E3 ligase recognition, binding, and ubiquitination. The degron-based substrates consist of 
four essential components: the degron for E3 ligase recognition and binding, an ubiquitination site 
lysine, a linking region to prevent steric hindrance issues, and a fluorescent tag for visualization 
(Figure 3).2 The fluorescent tag, normally 5,6 carboxyfluorescein, allows for visualization of the 
reporter through either gel electrophoresis, HPLC, or capillary electrophoresis. This previous study 
resulted in the optimization of a previously described synthetic degron, termed Bonger2,  to identify the 
minimal amino acid sequence still capable of ubiquitination. We found that a four  amino acid 
sequence (RRRG) could be efficiently ubiquitionated, which exhibits the potential to be incorporated 
into a novel proteasome reporter. This work was recently published in PLOS ONE2, but was not 
included in this document due to size  considerations. Additionally, as part of this study, we developed 
a degron-based substrate based on amino acids 92 to 112 from p53, as a reporter for evaluating MDM2 
activity. This specific sequence was demonstrated  be necesarry for MDM2 mediated degradation.2 
Our previous work demonstrated that the p53 degron-based substrate exhibited a high degree of 
ubiquitination as well as rapid reaction kinetics in comparison to other degron-based substrates, which 
has prompted further exploration of this region of p53 
for use in an E3 ligase MDM2 reporter.2 
 
A successful reporter for MDM2 activity needs to be 
easily synthesizable and resistant to intracellular 
peptidases, enzymes that hydrolyze the peptide bonds 
of small proteins, which requires that the degron-
based substrate consists of a minimal sequence of 
amino acids capable of binding to the target protein. 
This is important because the substrate needs to 
incorporate a peptidase-resistant sequence, termed a 
protectide, to prevent rapid degradation by 
intracellular peptidases. Previous work in the Waters 
lab has identified several protectides and utilized them to stabilize peptide-based kinase reporters.11 To 
address these goals, we aim to identify the minimal functional degron sequence based on the 
previously tested p53 degron-based substrate by utilizing a shotgun synthesis approach to create a 
library of substrates of varying lengths, which will be tested for MDM2-mediated ubiquitination. The 
shotgun method involves synthesizing smaller, overlapping sequences of the known p53 degron and 
testing them with an in vitro ubiquitination assay using multiple analytical techniques. Novel 
information about the minimal functional degron and its subsequent ubiquitination by MDM2 in an in 




Figure 3. Degron-Based Substrate Layout. A 
previously developed substrate capable of in vitro 





Materials and Methods 
 
Substrate synthesis and purification.   
Substrates were synthesized as previously described.2 Briefly, peptides were synthesized by solid 
phase peptide synthesis (SPPS) on a Creosalus Thuramed Tetras Automated Peptide Synthesizer using 
150 mg of CLEAR-amide resin. Amino acids were activated with HBTU (4 eq), HOBT (4eq), and 
DIPEA (5eq) in DMF and NMP. Deprotection of the peptide N-terminus was conducted in 2% DBU 
and 2% piperidine in DMF for 2 x 15 min each. Amino acid coupling steps were performed twice for 
30 min or 1 hr for natural amino acids and once for 4 hr in the case of Fmoc-Lys(ivDde)-OH. 
Acetylation of peptide N-termini was accomplished with 5% acetic anhydride and 6% 2,6-lutidine in 
DMF for 40 minutes. The Fmoc-Lys(ivDde)-OH side chain was deprotected with 3% anhydrous 
hydrazine in DMF for 3 cycles of 5 min each. Removal of the protecting group was confirmed by a 
Kaiser test.  Conjugation of the fluorescent tag was performed with either 5,6-carboxy-fluorescein 
(4eq) or 6-carboxy-fluorescein (4eq) combined with PyBOP (4eq), HOBT (4 eq), and DIPEA (4eq) in 
DMF reacting in a dark environment overnight.2 The peptide was cleaved from the resin using a 
mixture of TFA, TIPS and H2O in a 95:2.5:2.5 ratio, reacting for a minimum of 3 hr.  After the TFA 
was evaporated, the product was precipitated with cold ether, extracted into water, and lyophilized.  
 
Primary purification of peptides was performed via Reverse Phase HPLC using a C-18 semi-
preparative column in a Waters 2998 HPLC with photo iodide ray detector running absorbance 
detection at 214 nm and 490 nm. Gradients were run from polar, hydrophilic Solvent A (95% water, 
5% acetonitrile 0.1 % TFA) to non-polar/hydrophilic solvent B (95% acetonitrile 5% water 0.1%TFA). 
The lyophilized peptide was reconstituted in 10-15 mL of Solvent A and filtered using a Millex 0.22 
µL syringe driven filter. A trace was run using a 60 minute gradient of 0-100% B with a 200 µL 
sample injection. Traces were analyzed in collaboration with Adam Melvin to identify which peaks to 
collect. Peaks present in both 214 and 490 nm that were substantially greater than background noise, 
indicating the presence of fluorescein in combination with a peptide backbone were determined to be 
of importance and thus collected. The peptide was then purified via the above method using 1.0 mL 
injections and collecting the significant peaks. Eluent fractions containing substrate from primary 
purification were rotovapped using a Buechi Rotovapor R-200, lyophilized, reconstituted in solvent A, 
and subjected to secondary purification via reverse phase HPLC on the Waters 2998 HPLC. For 
secondary purification, a trace was run using a 100 minute gradient of 0-100% B with a 200 µL sample 
injection, and then analyzed according to peak presence at 214 nm and 490 nm.  Subsequent injections 
were increased to 1 mL and the remaining peptide was purified collecting only the top 50% of desired 
peaks to ensure purity. Eluent fractions containing the desired substrate were rotovapped and 
lyophilized. The presence of the desired peptide in first and second purification HPLC eluent fractions 
was verified using ESI or MALDI mass spectrometry. The mass spectrometry analysis was performed 
by either Gregory Woss or Brendan Peacor at the UNC Proteomics facility (MALDI) or the UNC 
Department of Chemistry Mass Spectrometry Facility (ESI), using an AB SCIEX 4800 PLUS MALDI-
TOF/TOF mass spectrometer. The purified peptide substrate was quantified using a Nanodrop 2000 
spectrophotometer, measuring the fluorescent activity of the FAM tag, to determine the concentration 
of peptide.  The peptides were reconstituted in 50 mM phosphate buffer and quantified by Beers Law, 
A=εlC, where A is the absorbance, ε the molar absorptivity, l the path length, and C the concentration). 






Ubiquitin pull down assay 
Peptide ubiquitination was evaluated using HeLa S100 cytosolic lysate-based ubiquitination assays 
combined with an antibody pull down specific for ubiquitin as previously described2. The assay was 
carried out at 37°C for 2 hrs at a total reaction volume of 100 µL. The assay consisted of buffer (10mM 
Tris-HCl Ph7.6 and 5mM MgCl2), 2mM DTT, 20 µg/mL ubiquitin aldehyde (Boston BioChem), 400 
µg/mL methylated ubiquitin (MeUb) (Enzo Life Sciences), 1X ATP-ERS (Boston BioChem), 100 µM 
proteasome inhibitor MG-132 (EMD Chemicals), 2mg/mL HeLa S100 cytosolic lysates as the source 
of E1, E2, and E3 enzymes, 4.2 µg of peptide substrate, and the inhibitors Complete ULTRA and 
PhosSTOP (Roche). After incubation, samples were incubated with Control-Agarose beads 
(LifeSensores), diluted in TBS-T buffer (20mM Tris-HCl pH 8.0, 150mM NaCl, and 0.1% Tween-20), 
for 60 min on a tube rotator at 4°C. Samples were then centrifuged to pellet the Control beads at 1800g 
for 5 min. The supernatant was transferred to a new tube to which a solution of Agarose-TUBES1 
(LifeSensor), diluted in TBS-T buffer, was added and then incubated overnight on a tube rotator at 
4°C. The purpose of these beads was to bind ubiquitin and anything conjugated to ubiquitin following 
a standard pull down or immunoprecipitation assay. Ubiquitin-bound beads were washed 5X with 
TBS-T buffer and samples were cleaved from the bead with 50 µL 2X tricine sample buffer, heated for 
5 min at >90°C, and isolated by centrifugation at 13000g for 5 min. Subsequently, samples were 
analyzed by gel electrophoresis (SDS-PAGE) using precast Bio-RAD Mini-PROTEAN® 16.5% Tris-
Tricine Gels. A fluorescent protein ladder (Benchmark, Life Technologies) was used as a means of 
comparing the molecular weight of samples run in the gel to predetermined values. Gels were run in 
1X Tris-Tricine Running Buffer (at 120V for ~ 90 minutes) and imaged at the Lineberger Cancer 
Center using a GE Typhoon Imager.  Scans were run with a photo multiplier tube (PMT) of 600 V and 
at 800 V using the Green 526 SP filter set and a pixel size of 100 microns was used.  
 
In vitro ubiquitination assay.  
Peptide ubiquitination was further evaluated using an in vitro ubiquitination assay. The reaction 
consisted of 10 mM Tris-HCl (pH 7.6), 2 mM MgCl2, 2 mM DTT, 300 µM ubiquitin, 1X ATP-ERS 
(Boston Biochem), 1 µM Ube1 (E1, Boston Biochem), 10 µM UbcH5b (E2, Boston Biochem), 1 µM 
HDM2 (E3, Boston Biochem), and varying concentrations of peptide substrate (1 µM, 5 µM, 10 µM, 
20 µM, and 30 µM) in a total reaction volume of 20 µL at 30 °C for 2 hrs. The reaction was halted by 
the addition of 40 µL Tricine Sample Buffer (BioRad), and samples were loaded onto SDS PAGE gels, 
electrophoresed and visualized as previously described using a GE Typhoon Imager.2 
 
Analysis of peptide ubiquitination by analytical HPLC 
Subsequent analysis of peptide ubiquitination was performed by analytical HPLC for more precise 
quantification. For this analysis, samples from the in vitro ubiquitination assay were immediately 
stored at -20°C to terminate the assay.  Analytical HPLC sample analysis utilized an Agilent 100 
HPLC system, a Phenomenex Jupiter 300 C-18 Column, and a fluorescence detector. Gradients were 
run from polar, hydrophilic Solvent A (99.9% water 0.1 % TFA) to non-polar/hydrophilic solvent B 
(99.9% acetonitrile, 0.1%TFA) for15 minutes. Assay samples were thawed to room temperature and 
then directly injected into the column for analysis. Additionally, samples were supplemented with a 
10µM fluorescein internal standard to aide in the quantification process, also termed “spiking” the 
analyte. A trace was performed using a 15 minute gradient of 0-100% B to identify the peaks found in 
the chromatogram. Traces were examined in Origin to determine peak identity. Significant peaks 
including: unmodified, or parent, peptide, ubiquitinated peptide, and internal standard, were integrated 




of each component present in the sample by a calculated comparison of the peak area of the sample to 











































Analytical parameters included resolution 
(R), number of theoretical plates (N), and 
plate height (H) and were calculated as 
follows. Using the average width, W1/2 
AVG, of two peaks of interest at half height 
(Eq. 1), values for resolution, , were 
determined by multiplying the difference 
in resolution of the two peaks, ΔtR, by a 
constant and dividing by W1/2 AVG (Eq. 2). 
The number of theoretical plates was 
determined by taking the square of the 
retention of one peak tR and multiplying 
by a constant and dividing by its width at 
half height, W1/2 (Eq. 3). Finally, 
theoretical plate height was calculated by 
dividing the column length, L, by the 




Iterations of the p53 degron-based substrate are differentially ubiquitinated 
All peptide substrates synthesized and tested in this study (Table 1) are based on the p53 degron 
identified by Gu and colleagues found to be necessary for MDM2 mediated degradation.12 We 
previously developed a substrate based on this degron and found that it exhibited pronounced 
ubiquitination kinetics.2 Further, we found that it could be multi-monoubiquitinated when multiple 
lysine residues were incorporated into the N- and C-termini (e.g., p53 v2 and v3, Table 1).8 Mono-
Table 1. p53 substrate library. A comprehensive list of all 
substrates synthesized for this study. Bold lysine residues 
correspond to the ubiquitination site lysine. The first sequence, 
p53 v2, represents the initial p53 sequence proven to be a strong 




ubiquitination refers to the conjugation of one 
ubiquitin molecule to one lysine residue on the 
substrate while multi-monoubiquitination refers to 
the conjugation of one ubiquitin molecule to 
multiple lysine residues within the substrate. Full 
length substrates (p53v2-v5, Table1) all exhibited 
varying degrees of mono-ubiquitination (Figure 5, 
lanes 1-5), and those with multiple free lysine 
residues exhibited multi-monoubiquitination 
(Figure 5, lanes 1-2). Due to the multi-
monoubiquitination of the full length substrate 
with multiple ubiquitination site lysines, shortened 
overlapping fragments based on the degron 
sequence were designed with a single 
ubiquitination site lysine to assess if they could be 
mono-ubiquitinated using a pull down assay 
incorporating HeLa cytosolic lysates. Three 
substrates (p53 v6-v8, Table 1) were designed for 
this study to isolate the minimal portable degron, 
the smallest functional region of the degradation 
sequence to be used for reporter targeting. 
Substrate p53 v6 was comprised of the amino 
acids immediately following the internal lysine 
residue and exhibited the strongest degree of 
ubiquitination of the shortened sequences (Figure 5, lane 5). Other abridged substrates, p53 v7 and v8, 
were also ubiquitinated to a lesser extent (Figure 5, lane 6-7). Due to the differential ubiquitination of 
these primary fragments in the ubiquitination pull down assays, it was decided to break these 
sequences into further fragments to continue the characterization of the minimal functional degron.  
 
It was decided to move away from the previously discussed pull down assay towards an in vitro 
ubiquitination assay designed to incorporate only the E1, E2, and E3 enzymes to minimize off target 
effects from the array of proteins and enzymes found in cellular lysates. Instead of using HeLa S100 
cytosolic lysates as a source enzymes, this new design incorporated purchased E1, E2, and E3 enzymes 
as the functional reaction components, eliminating the possibility of substrate degradation by 
intracellular proteases. By using purchased enzymes instead of cytosolic lysates, we were able to 
ensure that the only E3 ligase present in our assay was HDM2, providing specificity for the interaction 
of p53 and HDM2, which is of prime interest for our reporter. The entire library of substrates was 
subjected to this assay and exhibited varying degrees of ubiquitination (Figure 6).  By comparing 
relative band intensities (Figure 6), it was concluded that p53v6 and p53v11 exhibited the highest 
degrees of ubiquitination. Although SDS-PAGE analysis of the assay samples demonstrated 
reproducible results, proving the successful ubiquitination of library substrates, the established 
analytical limitations of this method prevented it gauging substrate ubiquitination at the desired level 
of precision.  
 
Figure 5. Gel electrophoretic analysis of in vitro pull 
down assay samples.  Gel results from previous work 
analyzing p53 substrates via in vitro pull down assay 
conditions showing the potency of the p53 degradation 
sequence as well as information about ubiquitination site 




Characterization of HPLC separation conditions to quantify p53-based substrate ubiquitination 
Based on the results 
obtained from the SDS-
PAGE analysis of the 
library of degron-based 
substrates (Figure 6), it 
was decided to utilize a 
more precise analytical 
tool to provide more 
quantifiable data on the 
degree of peptide ubiquitination. We decided to employ reverse phase analytical HPLC because it is a 
well-established, reliable analytical technique that also offers a high degree of precision measurement 
and the ability to quantitatively compare the degree of substrate ubiquitination. To effectively utilize 
HPLC as an analytical metric, we had to first identify the separation conditions for unmodified (or 
parent) peptide from ubiquitinated peptide for an octadecyl carbon chain (C18)-bonded silica analytical 
column. Separation conditions were determined using ubiquitination assay samples from the p53 v11 
peptide, a potent substrate based on our previous results. Based on previously established results from 
studies using HPLC to separate peptides and proteins,13 we employed a gradient of 99.9% water, 
0.1%TFA to 99.9% ACN, 0.1%TFA over a 15 minute time course using fluorescence detection to 
distinguish vital components of the assay sample. Parent peptide and ubiquitinated peptide 
(Ub~peptide) both contain a fluorescein tag, therefore fluorescence detection serves as the most 
effective method of identifying peaks of interest. Three peaks were present on chromatographic traces 
of assay sample corresponding to parent peptide (Figure 7A, 2), Ub~peptide (Figure 7A, 3), and an 
unidentified non-reactive species (Figure 7A, 1). Multiple control experiments were performed (Figure 
7B) removing E1 enzyme, E2 
enzyme, ubiquitin, or parent 
peptide, in order to identify the 
peaks corresponding to parent 
peptide and ubiquitinated peptide. 
We determined that peak 1, with a 
retention time of  ~4 minutes, was 
due to auto-fluorescence of a non-
reactive assay component which 
did not affect the migration and 
analysis of the ubiquitinated 
product. Peak 2, with a retention 
time of ~9 minutes, was identified 
as the parent peptide, while the 
smaller peak three, with a 
retention of ~10 minutes was 
determined to be ubiquitinated 
substrate. While we are confidant 
of this identification, further 
analysis using mass spectrometry 
of peak eluent is planned to 
completely characterize the 
Figure 7. Experimental characterization of HPLC separation 
conditions.  A) A sample HPLC trace of p53 v11 parent (1) and 
ubiquitinated (2) peptide were identified by the numbered peaks B) Control 
experiments, comprised of assay conditions lacking peptide (black), 
ubiquitin (purple), E1 (red), and E2 (blue) respectively, that verify the 
identity of characterized peaks C) Retention times and half widths of peaks 
relevant to the calculation of separation parameters, as well as calculated 
values that characterize the quality of separation. 
Figure 6. Gel electrophoretic analysis of enzymatic in vitro assay samples.  Gel 
results from the p53 substrate library subjected in vitro enzymatic assay conditions.  
Bands correspond to ~12kDa which was previously shown to be ubiquitinated peptide 




identity of each peak. However the results are pending due to backlog at the UNC Proteomics Facility. 
After successful characterization of peak identities in each assay sample, it was decided to incorporate 
an internal standard of 10 µM fluorescein. Comparison of assay sample traces spiked with internal 
standard to traces of pure fluorescein identified and confirmed that our chosen internal standard peak 
migrated with a retention time of ~12 minutes (Figure 8 A). We selected fluorescein as an internal 
standard because it has a different retention time than any peaks of interest from our assay sample, and 
it is important to correlate peak area to product concentration. The resolution between two adjacent 
peaks, indicative of the ability of HPLC conditions to separate a mixture, was calculated to be 3.81 
(Eq. 2). Additionally, a theoretical plate number of the separation was found to be 23,611 (Eq. 3) with 
a theoretical plate height of 0.11 nm (Eq. 4). These parameters are evidence of the quality and 
efficiency of the experimentally derived separation conditions. The successful discovery of analytical 
HPLC separation conditions allowed us to move forward with the project and more quantitatively 
screen the p53 substrate library for degree of ubiquitination.  
 
Quantification of p53-based substrate ubiquitination using HPLC 
With functional and effective separation conditions for the analysis of the in vitro ubiquitination assay 
samples, we set out to characterize substrate ubiquitination using analytical HPLC.  To properly 
characterize peptide ubiquitination we selected to calculate Michaelis-Menten kinetics by evaluating 
ubiquitin conjugation of the 
p53 based substrates of varying 
concentrations. When 
chromatography is performed 
with an internal standard of 
known concentration, peak 
areas can be used to calculate 
the concentration of each 
species of interest. Through 
integrating the desired signal 
peak, shown by the boundary 
bars in Figure 8B, one can 
obtain the selected peak’s area.  
Subsequently, the peak area of 
the known internal standard 
can be used to calculate a 
relative concentration for the 
peak of interest. Preliminary 
data extrapolated from HPLC 
analysis of substrates p53 v6 
and p53 v7 subjected to in vitro 
assay conditions are listed in 
Table 2. Data was obtained by 
quantifying peak area relative 
to known internal standard in 
order to determine the concentration of parent peptide and ubiquitinated peptide. In getting numerical 
values for the concentration of ubiquitinated peptide and parent peptide, we will be able to more 
accurately see the degree of ubiquitination of various substrate library members. Additionally, this will 
Figure 8. HPLC quantification of substrate ubiquitination. A) A sample 
HPLC trace for the separation and identification of parent and ubiquitinated 
p53 v6 peptide. B) Each peak was analyzed by selection and integration 
(Add more info here) C) A summary of peak areas center location, and 
estimated concentration of each species from the analysis of the 




allow for the precise characterization of reporter 
ubiquitination due to varying the initial concentration 
of parent peptide. Data representative of the 
concentrations of parent peptide and Ub~peptide will 
subsequently allow us to calculate the Michaelis-
Menten constants, Km and kcat, to precisely evaluate 
substrate performance. Preliminary experiments using 
p53 v6 and p53 v7 demonstrate that the concentration 
of Ub~peptide appears to increase in direct 
correlation to the initial concentration of parent 
peptide (Table 2). Unfortunately, it appears that the 
concentrations of parent peptide vary to some degree 
and do not correspond to the amount of parent peptide 
substrate originally used in the assay (Table 2). We 
are currently investigating this phenomenon to 
explore this inconsistency and determine the cause 
and its analytical implications. Nevertheless, the 
preliminary data obtain here provides the basis for a 
successful analysis of substrate ubiquitination to 
identify the minimal peptide sequence capable of 
MDM2-mediated ubiquitination.  Continued 
collection and analysis of peptide ubiquitination is 





In this project we attempted to identify and characterize the minimal amino acid sequence based on the 
naturally occurring degron found to be necessary for MDM2-mediated ubiquitination of p53. Based on 
the previous success of work with a p53 degron-based substrate, we employed a shotgun sequencing 
approach to synthesize a library of substrates of varying lengths and ubiquitination site lysine locations 
to find an ideal, yet minimized, recognition sequence for MDM2. Substrates were subjected to a HeLa 
S100 cytosolic lysate-based pull down assay and an enzyme only in vitro ubiquitination conditions, 
both analyzed by SDS-PAGE, to evaluate peptide ubiquitination. Subsequent analysis of the in vitro 
ubiquitination assay was performed by analytical HPLC to perform a more precise quantification about 
the degree of peptide ubiquitination. Initial examination of the p53 peptide-based substrates via the 
pull down assay showed successful mono-ubiquitination and multi-monoubiquitination of full length 
substrate sequences (Figure 5), validating the functionality of the p53 degron sequence proposed by Gu 
et al 12 for use in a degron-based substrate to assess  MDM2 activity. Next, the p53-based sequence, 
relatively large to be successfully utilized as a peptide-based reporter, was further broken down to 
identify if smaller iterations could retain the same degron potential. Evaluation of smaller fragments 
(p53 v6-8) by the ubiquitin pull down assay showed that these substrates exhibited varying degrees of 
ubiquitination (Figure 5), proving their functionality for use as a smaller functional degron. Substrate 
p53 v6, which was shown to be more strongly ubiquitinated than the other two fragments, was 
hypothesized to contain the smallest functional degron. With this successful minimization of the p53 
degron, efforts were made to further minimize this sequence to isolate the smallest portable degron. 
Table 2. Preliminary data from HPLC analysis 
of in vitro ubiquitination assay samples. 
Concentrations of parent peptide and ubiquitinated 
peptide product in samples of substrates subjected 
to in vitro assay conditions. Values were determined 
by peak area comparison to known internal 
standard. Concentrations of parent peptide not 
subjected to assay conditions are also included. 
Preliminary analysis explored the substrates p53v6 











Parent 10 µM 1.3 N/A
1 µM 0.43 0.0045
5 µM 0.94 0.02
10 µM 1.95 0.041
20 µM 3.55 0.063
p53v6 30 µM 5.89 0.088
Parent 10 µM 1.17 N/A
1 µM 0.47 0.0021
5 µM 0.99 0.02
10 µM 1.55 0.031
20 µM 2.9 0.05
30 µM 4.66 0.062
Parent 10 µM 1.54 N/A
1 µM 0.44 0.006
p53v7 5 µM 0.82 0.011
10 µM 1.89 0.015
20 µM 3.21 0.039




The ubiquitin pull down assay, using cell lysates as a source of E1, E2, E3 enzymes, provides 
functionality while also providing specificity to ubiquitinated product via the antibody pull down to 
ensure that what is seen on gel analysis is ubiquitinated peptide only. Alternatively, this type of assay 
poses certain limitations, such as the addition of unwanted cell lysate components like proteases and 
peptidases which can rapidly degrade the peptide-based substrate, and an unspecified number of 
functioning E3 ligases.  Therefore, for continued analysis of the shotgun sequenced substrates (p53 v6-
13, Table 1) an in vitro enzyme only assay was employed. In replacing the cell lysate source of UPS 
enzymes with purchased, specific E1, E2, and E3 enzymes, these assay conditions provided a more 
controlled environment, ensuring that observed E3 ligase activity was from HDM2 and was specific to 
its interaction with p53, while also removing the risk of substrate degradation via cytosolic peptidases. 
Substrates were analyzed via these new assay conditions and shown to be ubiquitinated to varying 
degrees (Figure 6). Further observation suggested that p53 v6 and p53 v11 exhibited the highest 
degrees of ubiquitination, suggesting that the smallest portable p53 degron of interest lies within this 
region. Additionally, the lack of observable ubiquitination of the negative control substrate p53 v13 
(Table 1, Figure 6), which lacks any free lysine residues for ubiquitination validates that the lysine 
residue is essential for substrate ubiquitination.  However, one limitation of using SDS-PAGE to 
analyze substrate ubiquitination is high signal-to-noise- ratio inherent in quantifying images of gels.  In 
fact, analysis of the negative control, p53 v13, failed to capture the observable results due to the high 
degree of background noise from using the Typhoon imager (data not shown). Overall these results 
from the gel electrophoretic analysis of assay samples point to p53 v6 and p53 v11 as being the most 
potent portable degrons of p53. However, due to the limitations of quantifying gels using ImageJ, a 
more precise and quantifiable method of assay samples analysis was explored. 
 
To perform a more precise analysis of the library of substrates, analytical HPLC analysis coupled with 
fluorescence detection was chosen.  This method not only provided a more numerical, quantifiable data 
analysis than SDS-PAGE, but was also a well-established, reproducible, stable analytical tool that can 
be applied to the detection of fluorescently tagged substrates. In order to proceed toward more 
quantitative analysis via analytical HPLC, separation conditions had to be experimentally determined 
for the separation of ubiquitinated peptide from parent peptide in the assay samples. Drawing form 
previous knowledge of peptide separation via reverse phase HPLC13, it was decided to use a gradient 
from water to acetonitrile across a 15 minute interval to determine if the two desired analytes could be 
effectively separated. Preliminary traces using fluorescence detection showed three peaks of unknown 
identity, suggesting that some assay component in addition to parent peptide and Ub~peptide all eluted 
off the column. In order to classify these unknown peaks, control experiments (Figure 7B) were run 
removing individual assay components to ascertain the identities of each peak from the trace. In 
comparing a complete assay sample (Figure 7A), with various controls that eliminated peptide 
ubiquitination, such as lack of E1, E2, and ubiquitin, established that peak 3 (Figure 7A) was present in 
all samples where the peptide was expected to be ubiquitinated, but absent in control experiments 
(Figure 7B). Therefore, we hypothesized that peak 3 was the ubiquitinated peptide product from in 
vitro assays. Additionally, a control experiment (data not shown) was performed where only parent 
peptide was run on the column to further verify that peak 2  (Figure 7A) corresponded to the peak 
observed in parent only control runs, further reinforcing the peak selection and identification. Having 
characterized peaks 2 & 3, we were still curious about the unknown peak labeled 1 (Figure 7A). This 
peak is seen to be present in all sample traces, but not in control traces of parent peptide only, E1 only, 
E2 only, and E3 only (data not shown). Therefore, we concluded that peak 1 must be due to auto-




of peak 1 being so distinct from the retention times of the desired analyte peaks, there is no concern 
about this non-reactive species being present in the HPLC trace and has since been deemed 
unnecessary for further analysis.  
 
Further, to confirm the characterization of eluent peaks in the HPLC analysis of the assay sample, 
fractions were collected and sent off to be analyzed via MALDI Mass Spectrometry. High traffic and 
use of the core facility at the UNC Proteomics facility has caused delay in obtaining these results, and 
the spectra for eluent fractions are still pending. Further, this type of analysis cannot be performed 
using the ESI in the Department of Chemistry due to the relatively high molecular weight of the 
Ub~peptide species (~8700 Da). In addition to successful peak identification, the calculation of 
analytical parameters such as resolution, number of plates, and plate height (Figure 7C) verify the 
quality of separation that is obtainable from these experimentally derived separation conditions. A high 
resolution, 3.81 (Figure 7C), demonstrates the degree and cleanliness of separation between the two 
desired peaks (2&3) on a chromatogram, thus verifying the ability of the overall procedure to separate 
and resolve the two solute compounds. A theoretical plate number of 23,611 (Figure 7C) further 
reinforces the quality of the experimentally determined separations conditions because in liquid 
chromatography, the separation of two compounds is enhanced by the increase in the number of 
theoretical exchange plates where solute and stationary phase interact increases. Finally, a small 
theoretical plate height, 0.11 nm, for the separation (Figure 7C) lends further credit to its quality 
because a small plate height is desirable for a chromatographic separation. The successful development 
of a procedure to separate parent and ubiquitinated peptide on an analytical column allowed us to move 
forward with more quantitative analysis of our p53 substrate library. 
 
Preliminary application of this experimentally determined HPLC procedure on samples using 
substrates p53 v6 and p53 v7 demonstrated an overall trend of increasing concentration of 
ubiquitinated peptide coupled with an increase in the initial concentration of parent peptide  (Figure 9). 
This suggested that these two degron-based substrates adhere to some type of characterizable kinetic 
behavior. Unfortunately, it was observed that the calculated concentration of parent peaks was 
significantly lower than the concentration of peptide used in assay conditions (Figure 9). This caused 
speculation of whether sample was being lost on the column during HPLC separation. The supposed 
loss of peptide seemed random and inconsistent across experiments using the same peptide substrate 
(Figure 9, p53 v6) and brought into question the functionality of HPLC as a tool for our desired 
analysis. If the amounts of peptide are lost inconsistently across different analytical runs for identical 
samples, it will be impossible to compare relative concentration across different traces and thus we 
would not be able to compare the degree of ubiquitination between substrates with this analytical 
approach. Due to this concern, experiments are currently underway using the p53 v6 substrate to 
determine if the ratio of parent peptide and ubiquitinated peptide seen in the eluent are consistent or 
variable. If loss is consistent due to a systematic error, then it can be compensated for and the 
analytical technique can be utilized with minor corrections.  
 
Another theory for the variation in calculated concentration of parent peptide and Ub~peptide 
originates from the calculation procedure using the internal standard peak area to quantify the other 
peak concentrations. Fluorescein is known to change its quantum fluorescent state sensitively to its 
surrounding environment; therefore it is likely that the pure FAM internal standard fluoresces stronger 
than FAM bound to ubiquitin. If this is the case, the direct one-to-one calculation using the peak area 




incompatible because the FAM-tag for each species is emitting varying degrees of fluorescence. 
Accordingly, further control experiments are planned to assess the difference in FAM fluorescent 
signal between the pure FAM internal standard and FAM bound to peptide. If the internal standard 
FAM is found to fluoresce more prominently than the FAM bound to peptide then the difference in 
signaling will propagate through the calculation of concentration, making the value lower than it 
should be. Therefore, we intend to proceed by no longer using the internal standard to calculate the 
concentration of product and parent peptide, but rather compare ratios of product to parent peptide 
across different analytical traces to compare their respective degree of ubiquitination. This eliminates 
the analytical problem due to possible inconsistencies from the FAM internal standard. Further 
speaking to the environment of the fluorescein tag and internal standard, we are aware that FAM 
fluorescence is highly pH sensitive, which is why we utilize pH controlled buffers in assay conditions, 
maintain a consistent amount of TFA in all HPLC solvents, and plan to run control experiments on 
fluorescence reproducibility. Once the corrected analytical procedure is determined from these further 
control studies, the entire substrate library will be subjected to in vitro enzymatic assay conditions 
combined with analytical HPLC analysis (Figure 8) to determine the ratio of ubiquitinated peptide to 
parent peptide. It is important to note that all of the data collected thus far can still be used for the 
subsequent analysis, so it is not necessary to repeat any of the above experiments.   
 
Using the ratios of parent to Ub~peptide for each substrate at varying initial peptide concentrations, we 
will be able to numerically compare the degree of ubiquitination of each substrate and use these values 
to assess the Michaelis-Menten (MM) kinetics for each of our substrates in the library, specifically the 
MM rate constants.  Michaelis-Menten kinetics is the most common biochemical technique to model 
enzyme-catalyzed alterations of a target protein that relates the reaction rate to the initial concentration 
of substrate. Through modeling the reaction rate over varying initial concentrations of substrate, this 
biochemical model allows for the determination of the maximum rate, vmax, of the enzymatic reaction 
as well as the Michaelis constant, Km, which is the value of substrate concentration when the reaction 
rate is at ½ vmax. By modeling the data obtained from HPLC analysis of assay samples with varying 
starting concentrations of parent peptide, we can determine the reaction rate, or degree of 
ubiquitination. By obtaining the Km and vmax for each member of the substrate library, we can compare 
the ubiquitination kinetics to determine which substrate is the most strongly ubiquitinated and contains 
the ideal portable degron sequence. This kinetic analysis allows us to further supplement the previous 
conclusion about the identity of the smallest portable degron of p53 based on the results from the SDS-
PAGE analysis for the identify of a potential MDM2 reporter. 
 
Once we have successfully obtained conclusions about the identity of the smallest portable degron, we 
have the opportunity for future work involving the quantitative exploration of inhibitors to MDM2. We 
intend to utilize the peptide-based reporter with the smallest functional degron sequence to assess the 
performance of certain MDM2 inhibitors to evaluate how these inhibitors limit the activity of MDM2 
on reporter ubiquitination by competitive inhibition for the p53 binding pocket in MDM2.  Such 
proposed work would provide a way of testing and comparing various MDM2 inhibitors to determine 
which are most effective. Such novel biomolecular and kinetic data would be of great value to 
investigators exploring the inhibition of the MDM2-p53 interaction as therapeutic drug target. 
Although a sparse number of reports relating to the UPS already exist10, most of these analytical tools 
are not compatible with single cell analysis and require lager populations of cells and complex genetic 
engineering.2 Recently, the analysis of single cells, especially primary cells obtained directly from 




a need for single cell reporters, to which degron based substrates provide the perfect 
complementation.2 Combining the proposed degron-based substrates into full single-cell reporters, 
incorporating β-hairpins as protecting motifs to stabilize the peptide-based reporter11, opens up a 
spectrum of UPS system to target in active cancer and tumor tissues.  
 
In conclusion, this study has demonstrated the effective development of a p53 degron-based substrate 
and performed preliminary analysis into the identification of a minimal portable degron that can be 
effectively incorporated into an analytical probe for MDM2 activity. Additionally, we have detailed 
the development of various analytical techniques including biochemical assays coupled with SDS-
PAGE or analytical HPLC to assess the degree of ubiquitination of the proposed degron-based 
substrates. By uncovering more information about p53, including new techniques of analyzing its 
interaction with its E3 ligase MDM2 and the precise sequence of the smallest effective degron, we are 
providing essential information of this essential enzymatic interaction. Future work based on this study 
includes MDM2 inhibitor performance analysis and the foundation for a new reporter of MDM2 
activity in single cells, both of which will expand the database of information about p53-MDM2 
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